Trial Profile
A trial to identify the additional selective biomarkers for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Pharmacodynamics
- 22 Jul 2016 New trial record